Doctors diagnose conditions that may warrant cognitive enhancers through structured clinical evaluations tailored to specific disorders, most commonly ADHD, narcolepsy, and Alzheimer’s disease. Each condition has defined diagnostic criteria, and in some cases, mandatory laboratory or sleep testing. There is no single screening test for cognitive enhancement, and no clinician can prescribe these medications on the basis of a general complaint about memory or focus.
The conditions most commonly treated with approved cognitive enhancers (stimulants like methylphenidate and amphetamine salts, wakefulness agents like modafinil, and cholinesterase inhibitors like donepezil) each follow their own diagnostic pathway. ADHD relies entirely on clinical and behavioral assessment. Narcolepsy requires objective sleep testing. Alzheimer’s has shifted toward a biology-based framework built around biomarkers. What all three share is that symptom reports alone are not sufficient.
Diagnosing ADHD: Clinical Interview and Behavioral Criteria
ADHD cannot be confirmed through a brain scan, blood test, or genetic analysis. The diagnosis is behavioral and clinical, governed by criteria in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
To meet the threshold for an adult diagnosis, a patient must show at least five symptoms in either the inattentive or hyperactive-impulsive category, present in at least two settings (such as home and work), persisting for at least six months, and causing measurable impairment in daily functioning. For adolescents and children under 17, the symptom count rises to six or more. Symptoms must also have been present before age 12, which typically requires corroboration from a parent or another informant who knew the patient in childhood.
The DSM-5 requires that symptoms not be better explained by another psychiatric condition, such as anxiety, a mood disorder, or a psychotic episode. This distinction matters in practice: stimulants prescribed for what turns out to be anxiety-driven inattention can cause significant harm.
A comprehensive evaluation includes a thorough diagnostic interview, standardized behavioral rating scales, DSM-5 symptom checklists, and information from independent sources such as a spouse or family member. Neuropsychological testing is not required but may be added in atypical presentations or when a learning disability is suspected.
Diagnosing Narcolepsy: Sleep Studies Are Mandatory
Unlike ADHD, narcolepsy cannot be diagnosed on symptoms alone, no matter how classic they appear. Objective testing is required. The American Academy of Sleep Medicine specifies that a new diagnosis must be confirmed either through sleep studies or through cerebrospinal fluid (CSF) hypocretin measurement.
The evaluation begins with a comprehensive sleep history and physical examination, including a neurological component. Before any testing, the clinician rules out other causes of excessive daytime sleepiness: insufficient sleep, circadian rhythm disorders, hypothyroidism, anemia, and psychiatric conditions. Sleep apnea in particular must be excluded before the daytime testing begins, because untreated apnea can shorten sleep latency and produce results that mimic narcolepsy. Medications with alerting or sedating effects, including antidepressants, should be tapered at least two weeks before testing where clinically safe, as they can produce false positive results.
The core diagnostic procedure pairs two sleep studies conducted back-to-back. The first is an overnight polysomnogram (PSG), which monitors brain waves, eye movements, muscle activity, and breathing across a full night of sleep. The following morning, the patient undergoes the Multiple Sleep Latency Test (MSLT): five scheduled nap opportunities at two-hour intervals, measuring how quickly the patient falls asleep and how quickly they enter REM sleep.
A positive MSLT requires a mean sleep latency below eight minutes, along with at least two naps in which REM sleep was reached (called sleep-onset REM periods, or SOREMPs). A SOREMP recorded during the overnight PSG, within 15 minutes of sleep onset, can count as one of the two required SOREMPs.
For narcolepsy type 1, characterized by cataplexy (the sudden loss of muscle tone triggered by emotion), a CSF hypocretin-1 level below 110 pg/mL can substitute for the MSLT entirely. This test is highly specific: levels that low are rarely seen in any other condition. In practice, CSF hypocretin testing is used selectively, most often in children, patients with atypical cataplexy, or those who cannot safely discontinue medications that would distort MSLT results.
HLA genetic typing for the DQB1*06:02 variant may be ordered as supporting evidence but cannot confirm a diagnosis. The variant is present in roughly 25% of the general population.
Diagnosing Alzheimer’s Disease: Clinical Evaluation Plus Biomarkers
Alzheimer’s diagnosis has shifted significantly over the past decade. The field moved away from relying on clinical symptoms alone, which can closely resemble depression, vascular dementia, or other conditions, toward a biology-based framework that uses biomarkers to confirm the presence of the disease’s defining pathology: amyloid-beta plaques and tau neurofibrillary tangles.
The 2024 Alzheimer’s Association clinical practice guideline establishes that the diagnostic process must begin with a comprehensive clinical evaluation. This includes a detailed history, cognitive and functional assessment, physical and neurological examination, and standard laboratory work to exclude treatable causes of cognitive decline such as thyroid dysfunction, vitamin deficiencies, or infection. Structural brain imaging is typically part of this initial workup.
Biomarker testing follows, rather than replaces, that clinical evaluation. It is recommended in patients with objective cognitive impairment, where establishing a biological diagnosis would change clinical management, for example by determining eligibility for anti-amyloid immunotherapy. Biomarker options include amyloid PET imaging, tau PET imaging, and CSF analysis for amyloid-beta and phosphorylated tau.
Blood-based biomarkers (BBMs) are increasingly available but subject to specific thresholds. The Alzheimer’s Association’s 2025 clinical practice guideline specifies that BBM tests with at least 90% sensitivity and 75% specificity may be used to rule out Alzheimer’s pathology. Tests reaching 90% sensitivity and 90% specificity can substitute for amyloid PET or CSF testing in specialized memory care settings. Many commercially available tests do not yet meet these thresholds. The most evidence-supported markers are plasma p-tau217, the ratio of p-tau217 to non-phosphorylated tau, p-tau181, p-tau231, and the Aβ42:Aβ40 ratio.
Biomarker testing in people without cognitive symptoms is not currently recommended outside of research studies, as no approved treatment exists for preclinical Alzheimer’s disease.
What All Three Processes Have in Common
In all three conditions, diagnosis is multi-step and draws on more than one source of information. Clinicians must rule out overlapping conditions before arriving at a diagnosis: anxiety and sleep deprivation can mimic ADHD, sleep apnea can resemble narcolepsy, and depression can present as dementia. Guidelines emphasize careful evaluation before prescribing these medications.
Functional impairment is a consistent requirement. A patient who shows symptoms but whose daily life is not meaningfully disrupted may not meet diagnostic criteria, regardless of what self-reported questionnaires indicate.
Who Performs These Evaluations
ADHD can be evaluated by a psychiatrist, psychologist, or primary care provider, though complex or adult-onset cases are often referred to specialists. Narcolepsy evaluations are conducted by sleep specialists, and sleep studies must take place in accredited sleep laboratories. Alzheimer’s evaluations typically involve neurologists, geriatricians, or memory specialists, particularly when biomarker testing is part of the workup.
Sources
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
- Banjo, O. C., Nadler, R., & Reiner, P. B. (2010). Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PLoS ONE, 5(12), e14322. https://doi.org/10.1371/journal.pone.0014322
- Centers for Disease Control and Prevention. (n.d.). Diagnosing ADHD. https://www.cdc.gov/adhd
- Children and Adults with Attention-Deficit/Hyperactivity Disorder. (n.d.). Diagnosis in adults. https://chadd.org
- Dickerson, B. C., Atri, A., Clevenger, C., et al. (2025). The Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care. Alzheimer’s & Dementia, 21(1), e14337. https://doi.org/10.1002/alz.14337
- Felt, B. T., Biermann, B., Christner, J. G., Kochhar, P., & Van Harrison, R. (2014). Diagnosis and management of ADHD in children. American Family Physician, 90(7), 456–464.
- Jack, C. R., Andrews, J. S., et al. (2024). Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia, 20, 5143–5169. https://doi.org/10.1002/alz.13859
- Kuol, P. P., et al. (2025). Exploring cognitive enhancers: From neurotherapeutics to ethical and regulatory challenges. Annals of Medicine & Surgery. https://doi.org/10.1016/j.amsu.2025.12333774
- Mahajan, R., & Gupta, R. (2020). Attention-deficit/hyperactivity disorder: Diagnostic criteria, epidemiology, risk factors and evaluation in youth. Translational Pediatrics, 9(Suppl 1). https://doi.org/10.21037/tp.2019.09.03
- Palmqvist, S., Whitson, H. E., Allen, L. A., et al. (2025). Alzheimer’s Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimer’s & Dementia, 21(7), e70535. https://doi.org/10.1002/alz.70535
- Ruoff, C., & Rye, D. (2016). The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: Clinical relevance and practicality. Current Medical Research and Opinion, 32(10), 1611–1622. https://doi.org/10.1080/03007995.2016.1199383
- Slowik, J. M., Collen, J. F., & Yow, A. G. (2025). Narcolepsy. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459236/
- Stanford Health Care. (n.d.). Diagnosis of narcolepsy. https://stanfordhealthcare.org
- American Academy of Sleep Medicine. (2015). Quality measures for the care of patients with narcolepsy. Journal of Clinical Sleep Medicine, 11(3), 335–355. https://doi.org/10.5664/jcsm.4554